Tissue Regenix eyes $1bn market

REGENERATIVE medical device group Tissue Regenix said today that it had made an important step towards commercialising its dCELL heart valve technology in a worldwide market worth $1bn.

The York-based company said that research into DCELL – which allows decellurlarised human heart valves to be used in heart surgery instead of common pulmonary valve substitutes – would be presented to a major medical congress by renowned cardiac surgeon Professor Francisco da Costa.

Tissue Regenix’s dCELL technology decellularises the heart valve making it inert and enabling it to be implanted into a patient to act as a mechanical scaffold that is populated by the patient’s own cells. The dCELL heart valve regenerates to become part of the patient’s body, providing a more durable repair with proven significantly reduced risk of rejection and infection.

Professor da Costa, who is based at Pontifical University of Parana, Brazil and is one of the company’s long term clinical collaborators, has been asked to present his dCELL heart valve findings at the 7th Biennial Congress of the Society for Heart Valve Disease & Heart Valve Society of America in Venice, Italy, on June 23.

Antony Odell, managing director of Tissue Regenix said: “We are pleased to see recognition for dCELL heart valve technology by this internationally distinguished congress. It is an important step towards the company’s commercialisation in this key area.”

Professor Francisco da Costa, research partner of Tissue Regenix said: “In this single institutional study, dCELL allografts have demonstrated superior results when compared to conventional cryopreserved allografts. In our experience, the decellularised valves seem to be providing superior reconstruction in these patients. It has been very gratifying to see such excellent results.”

The study used data from more than 400 patients over an eight-year period and found that patients had a less immunogenic reaction, no calcification, partial re-population of the grafts and there were particularly good results in younger patients.

Close